Osaka Soda (4046) · InitiativeFirst statedLatest Revision of earnings forecasts (2026-08-07): "Advanced"
Strengthening the VHH Antibody Development and Contract Manufacturing Business
First written in FY2026. 1 of 2 entries say "Advanced", first in 2026-08-07. Latest entry: 2026-08-07.
2entries
1years
1from disclosures
How it moved
Same theme, other companies
Expansion of Contract Antibody Generation and Peptide Synthesis ServicesA theme 5 companies write about · 0 as a headwind · 5 as a tailwind
2 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- 2026-08-07AdvancedRevision of earnings forecasts
「In the life science materials field, we aim to develop and commercialize materials that contribute to improved quality of life. By acquiring a partial stake in Epsilon Molecular Engineering Co., Ltd., we will strengthen our VHH antibody business in biopharmaceuticals.」
The Company has identified a partial investment in Epsilon Molecular Engineering Co., Ltd. as a specific means of strengthening its VHH antibody business. - FY2026First statedAnnual report
「「ライフサイエンス材料」の分野では、VHH抗体の開発製造受託事業を強化し、医薬関連やエイジングケアなどQOL向上に貢献する材料の開発および事業化を推進します。」
新事業創出の対象として、VHH抗体の開発製造受託事業と、医薬関連・エイジングケア等のQOL向上材料の開発・事業化を初めて具体的に記載している。